Cellid, Co., Ltd.

A299660

KR7299660001

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-06-25 pm EDT			5-day change	1st Jan Change
2,040 ^KRW	-5.99%		-19.21%	-54.36%

2023	Cellid, Co., Ltd.(KOSDAQ:A299660) dropped from S&P Global BMI Index	CI
2021	Private S.Korea firms plan $5.4 billion investment to create vaccine hub	RE

Cellid, Inc. has filed an IPO.

October 18, 2018 at 12:00 am EDT

Cellid, Inc. has filed an IPO. Security Name: Shares Security Type: Common Stock PriceRange: KRW 22100 to KRW 27000 Transaction Features: Sponsor Backed Offering

Latest news about Cellid, Co., Ltd.

Cellid, Co., Ltd.(KOSDAQ:A299660) dropped from S&P Global BMI Index	23-09-18	CI
Private S.Korea firms plan $5.4 billion investment to create vaccine hub	21-11-02	RE
SK bioscience : S.Korea to begin producing Novavax COVID-19 vaccine as early as June	21-04-12	RE
Cellid, Co., Ltd. announced that it has received KRW 19 billion in funding	21-03-18	CI
Cellid, Co., Ltd. announced that it expects to receive KRW 19 billion in funding	21-03-16	CI
Cellid, Inc.(KOSDAQ:A299660) added to S&P Global BMI Index	19-06-24	CI
Cellid, Inc.(KOSDAQ:A299660) added to S&P Global BMI Index	19-06-24	CI
Cellid, Inc.(KOSDAQ:A299660) added to S&P Global BMI Index	19-06-24	CI
Cellid, Inc. has completed an IPO in the amount of KRW 39.6 billion.	19-02-15	CI
Cellid, Inc. has filed an IPO.	18-10-18	CI
Cellid Co., Ltd. announced that it has received KRW 1.50 billion in funding from Amicogen Inc.	14-06-11	CI
Cellid Co., Ltd. announced that it expects to receive KRW 1.50 billion in funding from Amicogen Inc.	14-06-10	CI

Cellid, Co., Ltd. is a Korea-based company mainly engaged in the research and development of cancer therapeutic vaccine. The Company develops cancer therapeutic vaccine through development and clinical research of BVAC pipeline products using CeliVax original technology.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CELLID, CO., LTD.	-54.36%	21.22M
VERTEX PHARMACEUTICALS INCORPORATED	+16.49%	122B
REGENERON PHARMACEUTICALS, INC.	+21.73%	116B
ARGENX SE	+22.18%	27.03B
BIONTECH SE	-21.81%	20.36B
GENMAB A/S	-16.89%	16.43B
BEIGENE, LTD.	-18.81%	15.91B
WUXI APPTEC CO., LTD.	-44.74%	15.6B
SAREPTA THERAPEUTICS, INC.	+62.72%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+3.09%	13.59B